title: Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
authors.forename: David P
authors.identifier: http://orcid.org/0000-0001-5130-9284
authors.initials: DP
authors.lastname: Steensma
authors.affiliation: Amgen, Inc., Thousand Oaks, CA.
authors.forename: Barbra J
authors.initials: BJ
authors.lastname: Sasu
authors.affiliation: Mayo Clinic, Rochester, MN.
authors.forename: Jeff A
authors.initials: JA
authors.lastname: Sloan
authors.affiliation: Amgen, Inc., Thousand Oaks, CA.
authors.forename: Dianne K
authors.initials: DK
authors.lastname: Tomita
authors.affiliation: Mayo Clinic, Rochester, MN.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Loprinzi
mesh_terms: D000740:Anemia / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000068256:Darbepoetin alfa; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D064451:Hepcidins / Q000097:blood*; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic
chemical_list: D000970:Antineoplastic Agents; D006397:Hematinics; D064451:Hepcidins; D004921:Erythropoietin; D000068256:Darbepoetin alfa